Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - roxithromycin -

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

accedo arzneimittel gmbh (8073702) - roxithromycin - filmtablette - roxithromycin (23283) 150 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

stadapharm, gesellschaft mit beschränkter haftung (3080560) - roxithromycin - filmtablette - roxithromycin (23283) 300 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

stadapharm, gesellschaft mit beschränkter haftung (3080560) - roxithromycin - filmtablette - roxithromycin (23283) 150 milligramm

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

awd.pharma gmbh & co. kg (8040743) - roxithromycin - filmtablette - roxithromycin (23283) 300 milligramm

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - roxithromycin 300mg;   - coated tablet - 300 mg - active: roxithromycin 300mg   excipient: colloidal silicon dioxide glucose hyprolose hypromellose magnesium stearate maize starch povidone propylene glycol purified talc titanium dioxide water

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: glucose; propylene glycol; colloidal anhydrous silica; hyprolose; maize starch; povidone; hypromellose; magnesium stearate; titanium dioxide; purified talc - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; glucose; magnesium stearate; purified talc; povidone; titanium dioxide; maize starch; propylene glycol; hyprolose - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type b; colloidal anhydrous silica; titanium dioxide; propylene glycol; poloxamer; hypromellose; hyprolose; glucose; maize starch; sodium starch glycollate type a; purified talc; magnesium stearate; povidone - adults: the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms:- * upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. * lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. * skin and skin structure infections. * nongonococcal urethritis.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - roxithromycin -